WO2004010934A3 - Methods for the use of neurotoxin in the treatment of urologic disorders - Google Patents

Methods for the use of neurotoxin in the treatment of urologic disorders Download PDF

Info

Publication number
WO2004010934A3
WO2004010934A3 PCT/US2003/023349 US0323349W WO2004010934A3 WO 2004010934 A3 WO2004010934 A3 WO 2004010934A3 US 0323349 W US0323349 W US 0323349W WO 2004010934 A3 WO2004010934 A3 WO 2004010934A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
neurotoxin
treatment
urologic disorders
compositions
Prior art date
Application number
PCT/US2003/023349
Other languages
French (fr)
Other versions
WO2004010934A2 (en
Inventor
Rajiv Doshi
Original Assignee
Rajiv Doshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rajiv Doshi filed Critical Rajiv Doshi
Priority to AU2003259246A priority Critical patent/AU2003259246A1/en
Publication of WO2004010934A2 publication Critical patent/WO2004010934A2/en
Publication of WO2004010934A3 publication Critical patent/WO2004010934A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Abstract

Methods and compositions for treating urological disorders are provided. In the subject methods, an effective amount of a neurotoxin is intravesically delivered into the bladder lumen of a patient in need thereof. Also provided are compositions, e.g., pharmaceutical preparations and kits, for practicing the subject methods.
PCT/US2003/023349 2002-07-29 2003-07-25 Methods for the use of neurotoxin in the treatment of urologic disorders WO2004010934A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003259246A AU2003259246A1 (en) 2002-07-29 2003-07-25 Methods for the use of neurotoxin in the treatment of urologic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39954102P 2002-07-29 2002-07-29
US60/399,541 2002-07-29

Publications (2)

Publication Number Publication Date
WO2004010934A2 WO2004010934A2 (en) 2004-02-05
WO2004010934A3 true WO2004010934A3 (en) 2004-10-07

Family

ID=31188596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023349 WO2004010934A2 (en) 2002-07-29 2003-07-25 Methods for the use of neurotoxin in the treatment of urologic disorders

Country Status (3)

Country Link
US (1) US20040067235A1 (en)
AU (1) AU2003259246A1 (en)
WO (1) WO2004010934A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
AU2005327458B2 (en) 2005-03-03 2011-12-15 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
CA2610885A1 (en) * 2005-06-07 2006-12-14 David R. Staskin Injection guidance system and method
GB0610171D0 (en) 2006-05-23 2006-06-28 Robitaille Jean Pierre Valved nasal canula
WO2008101098A2 (en) * 2007-02-15 2008-08-21 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostata disorders, or hyperhydrosis
JP2011514308A (en) * 2007-10-23 2011-05-06 アラーガン、インコーポレイテッド Method for the treatment of genitourinary neurological disorders using modified Clostridial toxins
BRPI0911098A2 (en) 2008-04-04 2015-10-06 Lipella Pharmaceuticals Inc liposomal formulation and method for treating overactive bladder.
AU2012220564A1 (en) 2011-02-23 2013-08-29 Ams Research Corporation Drug releasing pelvic treatment system and method
JP6092205B2 (en) * 2011-07-14 2017-03-08 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ How to treat incontinence related to sexual activity
EP2760390B1 (en) 2011-09-29 2019-06-12 Trudell Medical International Nasal insert
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468239A (en) * 1992-04-13 1995-11-21 Sorenson Laboratories, Inc. Apparatus and methods for using a circumferential light-emitting surgical laser probe
US20020006905A1 (en) * 1993-12-28 2002-01-17 Allergan, Inc. Use of botulinum toxins for treating various disorders and conditions and associated pain
US20020025327A1 (en) * 1997-07-15 2002-02-28 University Technology Corporation Use of neurotoxin therapy for treatment of urologic and related disorders
US20020107199A1 (en) * 2000-12-05 2002-08-08 Allergan Sales, Inc. Methods of administering botulinum toxin
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5085650A (en) * 1989-10-20 1992-02-04 Giglio Frank A Gynecological urethral suppository
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5698549A (en) * 1994-05-12 1997-12-16 Uva Patent Foundation Method of treating hyperactive voiding with calcium channel blockers
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
EP0964691A4 (en) * 1996-07-22 2002-10-30 Cognetix Inc Use of conantokins
US6464697B1 (en) * 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
AU749201B2 (en) * 1997-08-28 2002-06-20 Afferon Corporation Urinary incontinence therapy
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6802841B2 (en) * 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
US6123703A (en) * 1998-09-19 2000-09-26 Tu; Lily Chen Ablation catheter and methods for treating tissues
US6200257B1 (en) * 1999-03-24 2001-03-13 Proxima Therapeutics, Inc. Catheter with permeable hydrogel membrane
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
PE20020063A1 (en) * 2000-06-20 2002-01-30 Upjohn Co BIS-ARYLSULFONES AS LIGANDS OF THE 5-HT RECEPTOR
MXPA03002918A (en) * 2000-10-02 2004-04-20 Arizeke Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE TRANSPORT OF BIOLOGICALLY ACTIVE AGENTS THROUGH CELLULAR BARRIERS.
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468239A (en) * 1992-04-13 1995-11-21 Sorenson Laboratories, Inc. Apparatus and methods for using a circumferential light-emitting surgical laser probe
US20020006905A1 (en) * 1993-12-28 2002-01-17 Allergan, Inc. Use of botulinum toxins for treating various disorders and conditions and associated pain
US20020025327A1 (en) * 1997-07-15 2002-02-28 University Technology Corporation Use of neurotoxin therapy for treatment of urologic and related disorders
US20020107199A1 (en) * 2000-12-05 2002-08-08 Allergan Sales, Inc. Methods of administering botulinum toxin
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery

Also Published As

Publication number Publication date
AU2003259246A1 (en) 2004-02-16
US20040067235A1 (en) 2004-04-08
WO2004010934A2 (en) 2004-02-05
AU2003259246A8 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2005009342A3 (en) Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005074913A3 (en) Compositions and methods for treating contracture
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
NO20050807L (en) Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders
MXPA05006940A (en) Therapeutic formulations for the treatment of beta-amyloid related diseases.
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2001052921A3 (en) Valve arrangement
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2003041686A3 (en) Improved therapy for topical diseases
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2004010934A3 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
NO20101070L (en) Method of dosing a drug, as well as dosage form
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
WO2002051379A3 (en) Thixotropic nasal spray
NO20051159L (en) Preparations and Methods for the Treatment of Diseases That Incorrectly Assemble Protein Aggregation
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP